bluuebunny/crossref_metadata_2025_split huggingface dataset:
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma
Authors: Ong Shin Yeu , Pak Stacy , Mei Matthew , Wang Yan , Popplewell Leslie , Baird John H. , Herrera Alex F. , Shouse Geoffrey , Nikolaenko Liana , Zain Jasmine , Godfrey James , Htut Myo , Aribi Ahmed , Spielberger Ricardo , Mansour Joshua , Forman Stephen J. , Palmer Joycelynne , Budde Lihua E. 
Published: September 2023

AbstractFludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard‐of‐care CAR T‐cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and address challenges including the recent national fludarabine shortage. We retrospectively evaluated outcomes among patients with relapsed/refractory aggressive B‐cell lymphoma who received bendamustine (n = 27) or Flu/Cy (n = 42) LD before axicabtagene ciloleucel (axi‐cel) at our institution. The median change in absolute lymphocyte count from pre‐LD to time of axi‐cel infusion was −0.6×109/L in bendamustine cohort and −0.7×109/L in Flu/Cy cohort. The best overall response/complete response rates were 77.8% (95% CI: 57.7%–91.4%)/48.1% (95% CI: 28.7%–68.1%) among bendamustine cohort and 81.0% (95% CI: 65.9%–91.4%)/50.0% (95% CI: 34.2%–65.8%) among Flu/Cy cohort. Six‐month progression‐free survival were 43.8% (95% CI: 24.7%–61.3%) and 55.6% (95% CI: 39.0%–69.3%) in bendamustine and Flu/Cy cohorts, while 6‐month overall survival were 81.5% (95% CI: 61.1%–91.8%) and 90.4% (95% CI: 76.4%–96.3%), respectively. Relative to Flu/Cy‐treated patients, bendamustine‐treated patients did not show an increase in hazards associated with experiencing progression/relapse/death (aHR:1.4 [95% CI: 0.7–2.8]; p = .32) or death (aHR:1.6 [95% CI: 0.5–5.6]; p = .46), after adjusting for baseline number of prior therapies and refractory disease. Any grade/grade ≥3 CRS were observed in 89%/3.7% and 86%/4.8% among bendamustine and Flu/Cy cohorts, while any grade ICANS/grade ≥3 ICANS were observed in 30%/19% and 55%/31% respectively. While more Flu/Cy‐treated patients experienced grade ≥3 neutropenia compared with bendamustine‐treated patients (100% vs. 68%), grade ≥3 infectious complications were comparable (24% vs. 19% respectively). More patients received bendamustine LD and axi‐cel as outpatient than Flu/Cy cohort, without increased toxicities and with shorter median inpatient stays. In conclusion, we observed comparable efficacy and lower any grade ICANS among patients receiving bendamustine relative to Flu/Cy LD, followed by axi‐cel.
Association between age at menarche and cardiometabolic risk among Samoan adults
Authors: Oyama Sakurako , Duckham Rachel L. , Pomer Alysa , Rivara Anna C. , Kershaw Erin E. , Wood Ashlee , Fidow Ulai T. , Naseri Take , Reupena Muagututia S. , Viali Satupaitea , McGarvey Stephen T. , Hawley Nicola L. 
Published: September 2023

AbstractObjectivesRecent studies suggest that early menarche may increase cardiometabolic morbidity and mortality. Yet few studies have examined this association in the Pacific Islands, where obesity prevalence is among the highest globally. We sought to examine associations between age at menarche and cardiometabolic risk in Samoa.MethodsParticipants were from the Soifua Manuia study (n = 285, age 32–72 years) conducted in Samoa from 2017 to 2019. Logistic regressions were conducted to estimate odds of obesity, hypertension, diabetes, dyslipidemia, and metabolic syndrome per one‐year increase in age at menarche. Linear regressions were conducted to examine associations between age at menarche and continuous measures of adiposity, blood pressure, insulin resistance, and serum lipids.ResultsMedian age at menarche was 14 years (IQR = 2). After controlling for relevant covariates, each one‐year increase in age at menarche was associated with a 15% decrease (OR = 0.85, 95% CI: 0.72–1.01, p = .067) in odds of hypertension, but a 21% increase (OR = 1.21, 95% CI: 1.01–1.45, p = .044) in odds of diabetes and 18% increase (OR = 1.18, 95% CI: 0.98–1.42, p = .081) in odds of high total cholesterol. Each additional year in age at menarche was associated with a 1.60 ± 0.52 kg (p = .002) decrease in lean mass and 1.56 ± 0.51 kg (p = .003) decrease in fat‐free mass.ConclusionsAssociations between age at menarche and cardiometabolic risk may be population‐specific and are likely influenced by both current and historical nutritional and epidemiological contexts. Prospective studies are needed to clarify the role of childhood adiposity and other early life exposures on age at menarche and subsequent cardiometabolic risk.
Heterozygous gain of function variants in a critical region of RNF13 cause congenital microcephaly, epileptic encephalopathy, blindness, and failure to thrive
Authors: Taylor Alan , Kashyape Pawan S. , Jain Ruchi , El Naofal Maha , Tayoun Ahmad Abou 
Published: September 2023

AbstractMissense variants in the RNF13 gene have been previously known to cause congenital microcephaly, epileptic encephalopathy, blindness, and failure to thrive through a gain‐of‐function disease mechanism. Here, we identify a nonsense variant, expected to result in protein truncation, in a similarly affected patient. We show that this nonsense variant, residing in the terminal exon, is likely to escape nonsense‐mediated decay while removing a critical region for protein function, thus resulting in a gain‐of‐function effect. We review the literature and disease databases and identify several other affected individuals with overlapping phenotypes carrying distinct truncating variants in the terminal exon upstream of the putative critical region. Furthermore, we analyze truncating variants from the general population, namely, the Genome Aggregation Database (gnomAD), and provide additional evidence supporting our hypothesis, and ruling out haploinsufficiency as an alternative disease mechanism. In summary, our case report, literature review, and analysis of disease and population databases strongly support the hypothesis that heterozygous gain‐of‐function variants in a critical region of RNF13 cause congenital microcephaly, epileptic encephalopathy, blindness, and failure to thrive.
Improved Electrocatalytic Activity and Stability by Single Iridium Atoms on Iron‐based Layered Double Hydroxides for Oxygen Evolution
Authors: Cao Jing , Mou Tong , Mei Bingbao , Yao Pengfei , Han Ce , Gong Xue , Song Ping , Jiang Zheng , Frauenheim Thomas , Xiao Jianping , Xu Weilin 
Published: September 2023

AbstractFull understanding to the origin of the catalytic performance of a supported nanocatalyst from the points of view of both the active component and support is significant for the achievement of high performance. Herein, based on a model electrocatalyst of single‐iridium‐atom‐doped iron (Fe)‐based layered double hydroxides (LDH) for oxygen evolution reaction (OER), we reveal the first completed origin of the catalytic performance of such supported nanocatalysts. Specially, besides the activity enhancement of Ir sites by LDH support, the stability of surface Fe sites is enhanced by doped Ir sites: DFT calculation shows that the Ir sites can reduce the activity and enhance the stability of the nearby Fe sites; while further finite element simulations indicate, the stability enhancement of distant Fe sites could be attributed to the much low concentration of OER reactant (hydroxyl ions, OH−) around them induced by the much fast consumption of OH− on highly active Ir sites. These new findings about the interaction between the main active components and supports are applicable in principle to other heterogeneous nanocatalysts and provide a completed understanding to the catalytic performance of heterogeneous nanocatalysts.
Non‐Doped Blue AIEgen‐Based OLED with EQE Approaching 10.3 %
Authors: Han Pengbo , Lin Chengwei , Xia Erhan , Cheng Jiawei , Xia Qing , Yang Dezhi , Qin Anjun , Ma Dongge , Tang Ben Zhong 
Published: September 2023

AbstractAggregation‐induced emission (AIE) luminogens (AIEgens) are attractive for the construction of non‐doped blue organic light‐emitting diodes (OLEDs) owning to their high emission efficiency in the film state. However, the large internal inversion rate (kIC(Tn)) between high‐lying triplet levels (Tn) and Tn‐1 causes a huge loss of triplet excitons, resulting in dissatisfied device performance of these AIEgens‐based non‐doped OLEDs. Herein, we designed and synthesized a blue luminogen of DPDPB‐AC by fusing an AIEgen of TPB‐AC and a DMPPP, which feature hot exciton and triplet‐triplet annihilation (TTA) up‐conversion process, respectively. DPDPB‐AC successfully inherits the AIE feature and excellent horizontal dipole orientation of TPB‐AC. Furthermore, it owes smaller kIC(Tn) than TPB‐AC. When DPDPB‐AC was applied in OLED as non‐doped emitting layer, an outstanding external quantum efficiency of 10.3 % and an exceptional brightness of 69311 cd m−2 were achieved. The transient electroluminescent measurements and steady‐state dynamic analysis confirm that both TTA and hot exciton processes contribute to such excellent device performance. This work provides a new insight into the design of efficient organic fluorophores by managing high‐lying triplet excitons.
Lightweight and self‐healing thermally expandable microsphere/silver composites with segregated conductive network for high‐efficiency electromagnetic interference shielding
Authors: Wei Huan , Luo Haihang , Wang Li , Gao Qiang , Chen Yi , Xiang Jun , Fan Haojun 
Published: September 2023

AbstractPolymer‐based electromagnetic interference (EMI) shielding materials with lightweight, self‐healing and high shielding performance show a wide application in electronics, medicine, national defense, aerospace and other fields. However, the conflict between a good conductive network structure and obtaining low density and excellent self‐healing property brings about tremendous challenges for fabricating these polymer‐based materials. Herein, a lightweight and self‐healing thermally expandable microsphere / silver (TEM/Ag) EMI shielding composites were prepared through a thermal foaming process. Due to the segregated Ag conductive network and expanded porous microsphere structure, the TEM/Ag composites possessed low density (0.095 g/cm3) and super‐high EMI specific shielding effectiveness (2816.3 dB cm2/g). In addition, benefiting from this unique structure, the composites exhibited excellent EMI shielding durability that can withstand ultrasonic washing 6 h (100 W), ethanol (99.5% purity), strong acid (pH 2.0), strong base (pH 12.0), NaCl solution soaking and long‐term air exposure (180 days). Furthermore, the inherent long‐chain entanglement imparts the composites a self‐healing feature, and 86% of the EMI shielding effectiveness can be maintained after self‐healing procedure.
Preparation of modified CO2‐based polyurethane for wet‐type artificial leather with excellent alkali resistance
Authors: He Zonglin , Huang Zhenhong , Chen Jiahui , Chen Ansheng , Ai Jiaoyan , Song Lina , Liu Baohua 
Published: September 2023

AbstractPoly (propylene carbonate) diol (PPCD) is one of the most attractive CO2 copolymers. PPCD‐based polyurethane has excellent mechanical properties and hydrophilicity, and is widely used in various fields. However, poor alkali resistance limits the application of PPCD‐based polyurethane in wet‐type artificial leather (WPL). In order to solve this problem, polyurethane solution (PUS) for wet‐type artificial leather was prepared by using PPCD and polytetramethylene ether glycol (PTMG) as soft segments. The chemical structure, viscosity, molecular weight and distribution, physical and mechanical properties, thermal properties and dynamic mechanical thermal properties of PUS were characterized. The changes of the physical and mechanical properties of PUS films and surface morphology of WPLs after soaking in 10 wt% NaOH solution at room temperature for 24 h were studied, so as to evaluate the alkali resistance of polyurethane. The retention of tensile strength and tearing strength of PUS films modified by PTMG increased from 80% to 96% and from 89% to 100%, respectively. The scanning electron microscopy results showed that appropriate PTMG was beneficial to the formation of microporous structure for CO2‐based polyurethane leather. The leather without PTMG showed agglomeration phenomenon, the micropores were not obvious, and the changes were obvious after soaking in alkali solution. After being modified by PTMG, the morphology of leather after soaking in alkali solution was basically unchanged. Polyurethane leather prepared with PTMG and PPCD as soft segments has excellent alkali resistance. These results suggest that PPCD could be a potential artificial leather material.
Single nucleotide polymorphisms in the CDH18 gene affect growth traits in Hu sheep
Authors: Liu Tianyi , Bi Yazhen , Bao Jingjing , Shang Mingyu , Hu Wenping , Zhang Li 
Published: September 2023

AbstractGrowth traits are critical economic traits in sheep. Genetic polymorphism has a great influence on the improvement of sheep traits. The aim of this study was to analyze the effect of cadherin 18 (CDH18) gene polymorphisms on growth traits in Hu sheep. The single nucleotide polymorphisms (SNPs) of the CDH18 gene in Hu sheep were identified by Illumina Ovine SNP 50K BeadChip. Five SNPs were screened out within the CDH18 gene, where SNP1 (rs423955510) was located in exon and SNP2 (rs412944692), SNP3 (rs416959317), SNP4 (rs398980439) and SNP5 (rs428685044) were located in intron. The expression of the CDH18 gene in Hu sheep tissue was analyzed using quantitative real‐time polymerase chain reaction, and the structure and phylogeny of the gene were analyzed using bioinformatics techniques. The results showed that SNP1, SNP2, SNP4, and SNP5 were significantly associated with body weight and body size (p < 0.05). Meanwhile, there were strong linkage disequilibrium relationships between SNP1 and SNP2 (r2 > 0.33). The CDH18 gene was expressed in the muscle tissues of Hu sheep at different months. The relative expression levels at weaning and 4‐month muscle tissue were higher. Bioinformatic analysis revealed that SNP1 existed in the 5′ untranslated regions, which might affect the efficiency of translation. The above findings suggested that these SNP loci might affect growth traits and could be regarded as potential molecular markers for improving the growth performance of Hu sheep, which lay a molecular foundation for the breeding of sheep and accelerate the pace of sheep breeding.
Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial
Authors: Gattorno Marco , Obici Laura , Penadés Inmaculada Calvo , Kallinich Tilmann , Benseler Susanne , Dekker Elise , Lévy Jérémy , De Benedetti Fabrizio , Lachmann Helen 
Published: September 2023

ObjectiveWe aimed at assessing efficacy, safety, and tolerability of canakinumab in patients with tumor necrosis factor receptor–associated periodic syndrome (TRAPS) during a 72‐week long‐term, open‐label extension of the CLUSTER study.MethodsPatients received open‐label canakinumab 150 or 300 mg, either every 4 weeks (q4w) or every 8 weeks, with up‐titration permitted after on‐treatment flares (maximum dose: 300 mg q4w). Efficacy assessments included physician global assessment of disease activity, number of flares, and serum C‐reactive protein (CRP) and serum amyloid A protein (SAA) levels. Adverse events were also reported. Results are described for the overall population and according to the cumulative dose of canakinumab adjusted for body weight (<36 mg/kg or ≥36 mg/kg).ResultsOf 53 patients entering the final phase (epoch 4) of CLUSTER, 51 completed the treatment. At the end of epoch 4, >94% of patients achieved no or minimal disease activity. Most patients had either no (69.8%) or one flare (24.5%), whereas at baseline, the median number of flares was 9.0 per year. Median CRP levels remained at <10 mg/L. Median SAA concentrations were largely unchanged, with medians of 11.5 mg/L and 14.5 mg/L in the <36 mg/kg and ≥36 mg/kg groups, respectively, at the end of the study. No unexpected safety findings were identified.ConclusionControl of disease activity, with low flare incidence, was maintained with long‐term canakinumab treatment in patients with TRAPS during the 72‐week final epoch of the CLUSTER study, with no new safety findings.
Piecewise fractional Legendre functions for nonlinear fractional optimal control problems with ABC fractional derivative and non‐smooth solutions
Authors: Zhagharian Shabnam , Heydari Mohammad Hossein , Razzaghi Mohsen 
Published: September 2023

AbstractIn this study, to solve fractional problems with non‐smooth solutions (which include some terms in the form of piecewise or fractional powers), a new category of basis functions called the orthonormal piecewise fractional Legendre functions is introduced. The upper bound of the error of the series expansion of these functions is obtained. Two explicit formulas for computing the Riemann–Liouville and Atangana–Baleanu fractional integrals of these functions are derived. A direct method based on these functions and their fractional integral is proposed to solve a family of optimal control problems involving the ABC fractional differentiation whose solutions are non‐smooth in the above expressed forms. By the proposed technique, solving the original fractional problem turns into solving an equivalent system of algebraic equations. The established method accuracy is studied by solving some examples.
Graph‐theoretic approach to finite‐time synchronization and topology identification of delayed multi‐group models with stochastic perturbation and multiple dispersal
Authors: Feng Yuli , Zhang Chunmei , Chen Huiling , Li Ran 
Published: September 2023

AbstractThis paper investigates the issue of finite‐time synchronization and topology identification of delayed multi‐group models with stochastic perturbation and multiple dispersal. Based on the graph‐theoretic approach, a novel finite‐time topology identification scheme is proposed via drive‐response synchronization. Then, several useful finite‐time topology identification criteria are presented. The topology identification of delayed multi‐group models with stochastic perturbation and multiple dispersal is acquired in finite time under the desired feedback controller. Finally, a numerical example is given to validate the effectiveness of the result developed.
Zika virus screening during pregnancy: Results and lessons learned from a screening program and a post‐delivery follow‐up analysis (2016–2022)
Authors: Martínez‐Arias Andrés , Valerio Lluís , Roure‐Díez Sílvia , Fernández‐Rivas Gema , Rivaya Belén , Pérez‐Olmeda Maria T. , Soldevila‐Langa Laura , Parrón Ignasi , Clotet‐Sala Bonaventura , Vallès Xavier , Rodrigo Carlos 
Published: September 2023

AbstractObjectiveTo evaluate a Zika virus screening program applied to asymptomatic exposed pregnant women.MethodologyAnalysis of data generated during the roll out of a Zika screening program. We included socio‐demographic data, ultrasounds, and serological results (IgM, IgG, and Plaque Reduction Neutralization Test; PRNT) from asymptomatic pregnant women exposed to Zika virus enrolled in the screening program between 2016 to 2019.ResultsWe included 406 asymptomatic ZIKV‐exposed pregnant women who gave 400 full‐term new‐borns. The median age was 30 years (IQR = 25–34), which was lower (29 years; IQR = 24–34) among women of non‐EU migrant origin (76.4% of the sample). Migrant women tended to delay the first pre‐natal consultation compared to EU origin women (p = .003). Overall, 83.2% (N = 328) of participants had ZIKV low risk serological profile (IgM−/IgG− or IgM−/IgG+ and PRNT‐), 3.0% (N = 12) showed high risk of recent ZIKV infection (IgM+ or PRNT+) and 13.7% (N = 54) had indeterminate results. A fetal malformation was identified in 29 children (9.3%). Fetal malformation was associated with a ZIKV high risk serological profile [24 out of the 246 (1.6%) with low risk profile and 3 out of the 12 with at high risk profile (25.0%; p = .02)]. Four newborns with high risk profile had a positive ZIKV‐PCR test, which included two cases with microcephaly. No association was observed between maternal exposure to ZIKV infection and developmental abnormalities during the post‐natal period follow‐up.ConclusionsThe ZIKV‐screening program had considerable costs and yielded a high rate of indeterminate results among asymptomatic pregnant women. Considering the poor value for decision‐making of the results, efforts should focus on providing early access to routine maternity care, especially to migrant women. A simpler screening protocol might consider an initial ZIKV‐PCR or IgM determination and subsequent referral to a fetal medicine specialist in those women with a positive result and/or whom ultrasound examination has revealed fetal abnormalities (10% of total women in our study sample).
Industriestandard Carbonbeton – durch Standards in eine ressourcenschonende Art des Bauens
Authors: Aldermann Kristina , Schumann Alexander , Rudloff Tobias , Zernsdorf Kai , Wiel Romy , Michler Harald 
Published: September 2023

AbstractDas Bauen nachhaltiger zu gestalten – das ist die Herausforderung! Damit dies gelingt, ist ein grundlegender Wandel im Bauwesen notwendig. Einen wesentlichen Beitrag dazu liefert der Werkstoff Carbonbeton. Mit dem Ziel, die notwendigen Grundlagen für eine klimabewusste Bauweise zu schaffen, startete im Januar 2022 das im Rahmen des BMBF‐Programms RUBIN (Regionale unternehmerische Bündnisse für Innovation) geförderte Forschungsprojekt Industriestandard Carbonbeton (ISC). In diesem Projekt werden fehlende Standards und Leitfäden für das Bauen mit Carbonbeton im Neubau geschaffen. Denn erst durch das Vorliegen von Standardisierungen und den Abbau von Barrieren bei der Anwendung für Planer, Bauherren, Hersteller und ausführende Unternehmen kann Carbonbeton wirtschaftlich und mit einem hohen Absatz in der Baubranche Akzeptanz finden. An dieser Stelle setzt der ISC an und liefert das fehlende Puzzleteil für den Einsatz von Carbonbeton. In nachfolgendem Beitrag werden die Projektpartner, die Ziele des Industriestandards, ausgewählte Forschungsaktivitäten und ‐ergebnisse vorgestellt sowie ein Ausblick auf die weiteren Arbeiten gegeben.
Transformieren statt Ersetzen – Umnutzung Felix‐Platter‐Spital, Basel
Authors: Kunze Matthias , Gianoli Andreas 
Published: September 2023

AbstractDas denkmalgeschützte Gebäude des ehemaligen Felix‐Platter‐Spitals in Basel wurde in einen gemeinschaftsorientierten Wohnungsbau mit 130 Wohnungen, das sogenannte „Miteinanderhaus“, umgenutzt. Das im Wettbewerb erarbeitete Konzept zielte darauf ab, das bestehende Stahlbetongebäude mit den Hauptabmessungen 100 m×20 m×35 m in seiner Erscheinung und Tragstruktur weitgehend zu erhalten. Ein neues doppelstöckiges Foyer sowie ein Erschließungskorridor mit kaskadenartiger Treppe und neuen Treppenhäusern bildeten die wesentlichen Veränderungen des Bestands. Tragwerkseitig erfolgten die Übernahme der vorhandenen Tragachsen und eine Beschränkung der Auf‐ und Nutzlasten auf die ursprünglichen Werte. Im Zuge der Umnutzung wurde eine Erdbebenertüchtigung mit ergänzenden Aussteifungsmaßnahmen durchgeführt. Die neuen Erdbebenelemente wurden mit Mikropfählen im Baugrund verankert. Notwendige Brandschutzertüchtigungen konnten durch vertiefte rechnerische Untersuchungen auf Teilbereiche reduziert werden. Die Realisierung der Eingangshalle im Bestand wurde mittels temporärer Sprießtürme gewährleistet. Abfangscheiben und Sichtbetonstützen bilden das neue Tragwerk des Foyers. In einer überzeugenden interdisziplinären Kooperation gelang die erfolgreiche Transformation eines Baudenkmals. Der Devise „Umnutzen statt Abbrechen“ folgend wurde hier ein vorbildhaftes Modellprojekt der Ressourcenschonung realisiert.